The Latest Cardiac and Vascular News
Funding Will Support Clinical Studies of the VelocityTM pAVF System in Patients with Chronic Kidney and End-Stage Renal Disease (Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced the […]
WEST VALLEY CITY, Utah, Sept. 9, 2024 /PRNewswire/ — Scientia Vascular, a leader in neurovascular innovation, is pleased to announce the closing of a $14 million growth financing led by Piper Sandler Merchant Banking. The financing will enable Scientia to continue commercializing the…
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024
Half-year sales of €3.3 million, exceeding 2023 full-year sales 20 implants of the Aeson® artificial heart performed in the first half of 2024 17% cash-burn1 reduction compared to the first half of 2023 2024 anticipated annual sales of €8 to €12 million Other 2024 operational objectives on track Active exploration of […]
September 06, 2024 07:59 AM Eastern Daylight Time ATLANTA–(BUSINESS WIRE)–Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will present findings today at HRX 2024. The two studies showcase how Vektor’s advanced technologies uniquely leverage AI and deep learning to assess wall thickness and scar tissue in ventricular tachycardia […]
CHICAGO–(BUSINESS WIRE)–New international cardiology guidelines require the use of an ultrasound enhancing agent during stress echocardiograms to assess myocardial perfusion in patients with ischemia, as well as left ventricular heart function, according to a British cardiologist who is a co-author of the guidelines. “Lives are saved when ultrasound enhancing agents […]
PALM SPRINGS, Calif., Sept. 6, 2024 /PRNewswire/ — Leading physicians and researchers will present results from 21 clinical trials from Sunday, November 3, to Tuesday, November 5, at the annual VIVA and The VEINS conferences at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is a…
Benefits of transvenous implantable defibrillators, including anti-tachycardia pacing (ATP), in a single device implanted safely outside the vascular space: 77% ATP success rate, in line with transvenous ICDs Avoided shocks in nearly half of all ventricular tachycardia/ventricular fibrillation (VT/VF) episodes through 30.6 months average follow-up LONDON and GALWAY, Sept. […]
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.
New vice president of clinical affairs and board of directors member will support advancement of eLym™ System therapy for acute decompensated heart failure GALWAY, Ireland — September 5, 2024 — WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), today announced the appointments of Ric Cote to […]
